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Introduction: The occurrence of cardiac dysfunction is common after subarachnoid hemorrhage (SAH) and was
hypothesized to be related to the release of endogenous catecholamines. The aim of this prospective study was to
evaluate the relationship between endogenous catecholamine and cardiac dysfunction at the onset and during the
first week after SAH.
Methods: Forty consecutive patients admitted for acute SAH without known heart disease were included.
Catecholamine plasma concentrations and transthoracic echocardiography (TTE) were documented on admission,
on day 1 (D1), and day 7 (D7).
Results: At baseline, 24 patients had a World Federation of Neurosurgical Societies score (WFNS) of one or two; the
remaining 16 had a WFNS between three and five. Twenty patients showed signs of cardiac dysfunction on
admission, including six with left ventricle (LV) systolodiastolic dysfunction and 14 with pure LV diastolic
dysfunction. On admission, norepinephrine, epinephrine, dopamine, B-type Natriuretic Peptide (BNP) and Troponin
Ic (cTnI) plasmatic levels were higher in patients with the higher WFNS score and in patients with altered cardiac
function (all P <0.05). Among patients with cardiac injury, heart function was restored within one week in 13
patients, while seven showed persistent LV diastolic dysfunction (P = 0.002). Plasma BNP, cTnI, and catecholamine
levels exerted a decrease towards normal values between D1 and D7.
Conclusion: Our findings show that cardiac dysfunction seen early after SAH was associated with both a rapid and
sustained endogenous catecholamine release and WFNS score. SAH-induced cardiac dysfunction was regressive
over the first week and paralleled the normalization of catecholamine concentration.Introduction
Aneurysmal subarachnoid hemorrhage (SAH) is a
neurologic emergency. The incidence of the disorder has
remained stable over the past 30 years [1] with an aggregate
worldwide incidence of about 10.5 per 100,000 person-years
[2]. As many as 46% of SAH survivors suffer from* Correspondence: alexandre.mebazaa@lrb.aphp.fr
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status and quality of life [3-5].
Cardiac dysfunction is frequently observed after acute
SAH [6-9]. Meaudre et al. [10] found that B-type natriuretic
peptide (BNP) and troponin Ic (cTnI) were rapidly and
transiently elevated following SAH. Other studies have
shown an association between cTnI [9,11], BNP levels
[6], clinical SAH severity, and the presence of cardiac
dysfunction [11-13]. It has been suggested that the
pathophysiology of cardiac injury after SAH is similar
to apical ballooning syndrome (Takotsubo or stress
cardiomyopathy) that is, in relation to catecholamine
endogenous release [14]. Few human studies have showntd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dysfunction at an early stage after SAH, and to our
knowledge few human studies have focused on the time
course of catecholamine release and cardiac dysfunction
during SAH [5,15].
The primary aim of this work was then to confirm the
potential association between catecholamine release and
cardiac dysfunction during the early phase of SAH.




This prospective observational cohort study was conducted
in a university hospital, between June 2008 and May 2009.
Our local ethics committee approved the study (CEERB
Paris Nord number IRB00006477), and all patients or next
of kin provided written informed consent.
Inclusion criteria were as follow: patients >18 years
old admitted into the ICU with SAH documented by
cerebral computed tomography (CT) scan and angio-CT
scan [16]. The neurological status was assessed at the
time of ICU admission and graded according to the
World Federation of Neurosurgical Societies (WFNS)
scale and the CT scan Fisher score.
Exclusion criteria were: patients with known heart
disease such as cardiomyopathy, prior myocardial infarc-
tion or atrial fibrillation. Patients, families, or referring
physicians were interviewed to determine the date and
nature of the first signs or symptoms that were
clearly attributed to SAH. If delay from first sign or
symptom to arrival at our ICU exceeded 48 hours
after SAH symptoms, patients were not included.
Patients
All consecutive patients were admitted to our ICU and
were managed according to the recommendations of the
French Society for Anesthesia and Intensive Care for
SAH [17]. In particular, the culprit cerebral aneurysm
identified by angiography was treated as soon as possible
by either endovascular coiling or neurosurgical clipping
[18]. After the first echocardiography, patients were
classified in two groups: patients with no cardiac dysfunc-
tion versus patients with either left ventricular systolic
(left ventricular ejection fraction (LVEF) <50%) or diastolic
cardiac dysfunction defined by the criteria of the American
Society of Echocardiography [19]. Patients were also
classified in two groups according to the function of
the SAH severity: severe SAH (WFNS 3 to 5) or non-severe
SAH (WFNS 1 to 2).
Patient’s management and clinical data collection
Conscious patients were managed with bed rest, hydration,
oral nimodipine (Leverkusen) and analgesia. Managementof comatose patients included sedation with propofol (New
York City, New York) and sufentanyl (Sufenta®, Janssen-
Cilag, Belgium), ventilation, enteral feeding, oral nimodi-
pine, and monitoring of intracranial pressure (ICP) in cases
of intracranial hypertension.
During the first seven days, each patient received
intravenous (iv) isotonic saline at the dose of 30 to
40 ml/kg/day. The presence or absence of cerebral
vasospasm by transcranial Doppler was screened daily
during the ICU stay. In the event of vasospasm, suspected
due to apparition of a new neurological deficit in con-
scious patients or with asymmetric acceleration of the
transcranial Doppler flow, [20] additional fluid infusions
were administered. The mean arterial blood pressure was
maintained around 100 to 110 mmHg. If the patient
remained symptomatic despite fluid loading and high
blood pressure, arteriography was performed to treat the
vasospasm mechanically (artery dilatation with balloon) or
chemically (Nimotop®, Corotrope®) if needed [20].
If clinical signs of intracranial hypertension occurred
(ICP >20 mmHg) [21], exogenous norepinephrine was
administered to maintain cerebral perfusion pressure above
65 mmHg, and symptomatic hydrocephaly was managed
using external ventricular drainage.
Clinical and demographic data including age, sex, body
mass index, and body surface area were collected.
Exogenous catecholamine administration (for example,
norepinephrine) was recorded. Hyponatremia was defined
as a sodium level <135 mmol/L for at least two consecutive
days [22]. A 12-lead ECG (electrocardiography) was per-
formed daily for seven days. The ECG was considered ab-
normal if the T-wave was inverted or flattened, the ST
segment was elevated or depressed, the QT interval was
prolonged, or arrhythmia was present.
Biomarkers
Blood was drawn in EDTA at baseline, day 1 and day
7, centrifuged within 2 hours and plasma was stored
at −80°C until further analysis. After specific sample
preparation through solid phase extraction (Chromsystems
Instruments®), catecholamine plasma levels (epinephrine,
norepinephrine, dopamine,) were analyzed using an
isocratic HPLC system and an electrochemical detector
(Coularray, ESA). Usual normal values for catecholamine
plasma levels were <500, <2500 and <200 pmol/L for
epinephrine, norepinephrine and dopamine, respectively
[23]. cTnI levels were measured by ELISA (lower limit
of detection, 0.01 μg/L). For BNP measurement, arterial
blood was withdrawn in EDTA and placed within
30 minutes on a Triage B-Type Natriuretic Peptide test
slide and analyzed in the Biosite MeterPlus (Triage®)
machine, a point-of-care test based on fluorescence
immunoassay. The test has a range of 5 to 5,000 ng/L
(normal values <100 ng/L).
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At the same time as blood analysis, transthoracic echo-
cardiography (TTE) was performed on baseline, day 1,
and day 7 using a Vivid-i (General Electrics®) equipped
with 2.5-MHz transducers. All TTE was performed by
RS (Cardiologist and Intensivist) and FV (Intensivist and
anesthesiologist), who are both certified in echocardiography
and was performed blinded to all clinical, hemodynamic,
and biological data.
Patients were imaged in the supine position. Two-
dimensional images were obtained in the standard
parasternal and apical views. All echocardiographic
data were averaged from three to five end-expiratory
cycles. Left ventricular and left atrial dimensions were
measured according to the recommendations of the
American Society for Echocardiography. LVEF was
measured by Simpson's method [24]. Doppler recordings
were obtained at a sweep speed of 100 mm/s. Pulsed
Doppler was used to record transmitral flow in the
apical four-chamber view. Tissue Doppler velocities
were acquired at a lateral annular and septal site and
E’ mean were calculated as:
E’mean ¼ E’lat þ E’sepð Þ=2ð Þ:
Mitral inflow measurements included early peak (E)
and late peak (A) velocities, early peak (E) to late peak (A)
ratio and deceleration time (DT) of E velocity. These mea-
surements were analyzed as described previously [25]. The
systolic pulmonary artery pressure (SPAP) was estimated
using continuous-wave Doppler ultrasound measurement
of the peak velocity of a tricuspid regurgitant jet. Tricuspid
annular plane systolic excursion (TAPSE) was measured in
T-mode at the lateral side on the right ventricle. At base-
line, SAH patients were classified in two groups: pa-
tients with no cardiac dysfunction versus patients
with either LVEF <50% or diastolic cardiac dysfunction de-
fined by criteria of the American Society of Echocardiog-
raphy [19]. Of note, regional wall motion abnormalities
(RWMA) were not recorded in the present study as we
were interested to assess global meaningful right and/or
left ventricular function abnormalities.
Statistical analysis
Depending on whether the variables were normally distrib-
uted, the t-test or Mann-Whitney U-test was used to
compare quantitative variables and the Chi-square test
was used to compare qualitative parameters between
patients with or without cardiac dysfunction at ICU
admission and according to the clinical severity of
SAH. Continuous variables were expressed as median
(25th to 75th) percentiles. The analysis of catecholamine,
myocardial-injury marker concentration, and TEE-parameter
variation over time in each group were analyzed with theWilcoxon signed-rank test for non-normally distrib-
uted variables and the t-test for dependent samples in
the case of normally distributed parameters. Receiver
operator characteristic (ROC) curve analysis was used
to determine the best BNP and cTnI cutoff values in
order to predict the occurrence of cardiac dysfunction
at ICU admission. The level of significance was defined as




Forty-seven consecutive patients have been admitted
to our ICU with non-traumatic SAH. Seven patients
were excluded because of known heart disease such
as cardiomyopathy (n = 1), prior myocardial infarc-
tion (n = 4) or atrial fibrillation (n = 2). The charac-
teristics of the 40 SAH patients included and clinical
events are listed in Table 1.
The average time between the onset of SAH and ICU
admission was 10 ± 9 hours. Thirty-seven patients had
arteriography on admission: one or more aneurysms
were subsequently diagnosed in 35 patients (34 treated
by embolization and one by surgery) and no aneurysms
were diagnosed in 2 patients; 3 patients died before
arteriography. ICU mortality in the studied patients with
SAH was 17.5% (7/40) with much greater mortality in
patients with WFNS scores 3 to 5 than in those with
WFNS scores 1 to 2 (37 versus 4%; P = 0.006).
Cardiac dysfunction in SAH patients
The average time between ICU admission and the
completion of the first echocardiography was 14 ± 10
hours. Half of the included SAH patients (20/40) had
echocardiographic abnormalities at ICU admission.
The characteristics of SAH patients with and without
cardiac dysfunction on admission are shown in Table 2.
Table 3 further shows that left ventricular (LV) diastolic
dysfunction assessed by the marked fall in the E wave
(64 (50 to 94) versus 97 (83 to 102) cm/s, P = 0.004), in E’
lateral (7 (6 to 9) versus 15 (17 to 24) cm/s, P <0.0001), in
E’ mean (7 (6 to 8) versus 13 (11 to 16) cm/s, P <0.0001)
with no concomitant dilatation of the left atrium (15.6
(12.4 to 18.8) versus 15.9 (12.7 to 18.6) ml/m2, P = 0.59)
was present in all 20 patients with echocardiographic
abnormalities compared to patients with no cardiac
dysfunction on echocardiography. In addition to LV
diastolic dysfunction, 6/20 patients had moderate LV
systolic dysfunction (LVEF = 40% (25 to 49%), n = 6).
Concerning the right ventricle, TAPSE was lower in SAH
with LV abnormalities versus no LV abnormalities, though
this was not statistically significant (22 (20 to 24) versus
24 (21 to 27), P = 0.07). No echocardiographic signs of
Takotsubo were seen.
Table 1 Demographic, hemodynamic, echocardiographic, biological and outcome characteristics of SAH patients
All patients WFNS 1 to 2 WFNS 3 to 5 P-values
n = 40 n = 24 n = 16
Demographics parameters
Age, years 48 (39 to 57) 41.5 (31.5 to 51) 55 (46 to 67) 0.002
Female, n (%) 24 (60) 14 (54) 10 (62) 0.07
Body mass index, kg/m2 24.3 (22.6 to 26.1) 24.5 (23 to 26.1) 23.5 (22.3 to 26.2) 0.7
Fisher score 4 (3 to 4) 3 (1.5 to 4) 4 (4 to 4) 0.0006
Hemodynamic and respiratory parameters on admission
Mean arterial pressure, mmHg 85 (80 to 96) 83 (77 to 93) 90 (82 to 107) 0.1
Heart rate, beats per minute 66 (60 to 81) 65 (58 to 76) 76 (62 to 91) 0.04
PaO2/FiO2 ratio 421 (300 to 452) 445 (407 to 454) 355 (254 to 388) 0.03
PaCO2, mmHg 38 (37 to 40) 38 (37 to 40) 40 (35 to 43) 0.51
Mechanical ventilation, n (%) 20 (50) 4 (20) 16 (100) <0.0001
Echocardiographic parameters on admission
Left ventricular ejection fraction, % 64(44 to 66) 65 (60 to 66) 57 (44 to 66) 0.01
E’, cm/s 9.5 (6 to 13) 12.5 (8.6 to 14.4) 6.5 (6 to 8.7) <0.0001
TAPSE, mm 22 (19 to 26) 24 (21 to 27) 22 (20 to 23) 0.01
Myocardial biomarkers on admission
B-type natriuretic peptide, ng/L 214 (109 to 374) 202 (79 to 286) 298 (125 to 674) 0.02
Troponin Ic, μg/L 0.026 (0.01 to 1.06) 0.01 (0.01 to 0.28) 0.27 (0.02 to 4.64) 0.006
Catecholamine levels (see Figure 1)
Epinephrine (N: <500 pmol/L) 632 (337 to 1116) 602 (286 to 838) 754 (403 to 1656) 0.04
Norepinephrine (N: <2,500 pmol/Ll) 3,106 (1,913 to 6,803) 2,487 (1,620 to 3,243) 8,451 (4,432 to 35,059) 0.001
Norepinephrine after exclusion of patients receiving exogenous
norepinephrine (n = 35, 22 and 13 respectively)
2,754 (1,844 to 4,601) 2,487 (1,620 to 3,243) 5,834 (2,646 to 8,645) 0.006
Dopamine (N: <200 pmol/L) 178 (124 to 347) 155 (121 to 231) 320 (194 to 462) 0.01
Length of stay in ICU, days 10.5 (7.2 to 13.5) 10.4 (6.2 to 12.0) 13.2 (7.5 to 19.7) 0.07
Complications during ICU stay
Vasospasm, n (%) 9 (22) 5 (20) 4 (25) 0.1
Hyponatremia, n (%) 12 (30) 6 (25) 6 (37) 0.4
Seizure, n (%) 9 (22,5) 4 (16) 5 (31) 0.3
Death in ICU, n (%) 7 (17.5) 1 (4) 6 (37) 0.006
Aneurysm and neurologic management
Ventricular derivation, n (%) 13 (32) 2 (8) 11 (68) <0.0001
Arteriography, n (%) 37 (92) 24 (100) 13 (81) 0.06
Arterioembolization, n (%) 34 (85) 23 (96) 11 (68) 0.02
Data expressed as median (25th to 75th percentiles) or number (%). P-values for comparison between World Federation of Neurosurgical Societies (WFNS) scores
1 to 2 and WFNS scores 3 to 5. SAH, aneurysmal subarachnoid hemorrhage; FiO2, inspired oxygen fraction; PaO2, arterial partial pressure of oxygen; TAPSE,
tricuspid annular plane systolic excursion; N, normal value.
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abnormalities had two-fold greater plasma BNP, and
forty-fold greater cTnI. Of note, ROC analyses showed
that a BNP level >298 ng/L on admission was associated
with the presence of echocardiographic abnormalities in
SAH patients with sensitivity (Se) of 45% (23 to 68) and
specificity (Sp) of 85% (62 to 97), and cTnI >0.469 μg/l
was associated with echocardiographic abnormalities withSe of 50% (27 to 72) and Sp of 90% (68 to 99). Table 3
further shows that cardiac dysfunction was associated with
greater plasma levels of epinephrine, norepinephrine and
dopamine in SAH patients. This was also true, for
plasma levels of norepinephrine, after exclusion of the
five patients who received exogenous norepinephrine:
3,222 (2,480 to 7,516) versus 2,281 (1,519 to 3,264) pmol/L,
P = 0.01 with or without cardiac dysfunction respectively.
Table 2 Patients' characteristics as a function of presence of cardiac dysfunction on admission
No cardiac dysfunction on admission Cardiac dysfunction on admission P-values
n = 20 n = 20
Age, years 40 (31 to 50) 57 (46 to 64) 0.003
Female, n (%) 11 (55) 13 (65) 0.5
Body mass index, kg/m2, median 24.5 (22.2 to 26.2) 24.8 (22.6 to 26) 0.6
History of high blood pressure, n (%) 2 (10) 6 (30) 0.23
Diabetes mellitus, n (%) 0 (0) 0 (0) -
Chronic kidney failure, n (%) 1 (5) 0 (0) 0.9
Tobacco use, n (%) 4 (20) 1 (5) 0.34
Fisher score 3 (2 to 4) 4 (4 to 4) 0.003
WFNS score 1 (1 to 2) 4 (2 to 4) <0.0001
ECG anomalies, n (%) 2 (10) 3 (15) 0.6
Patients receiving norepinephrine, n (%) 2 (10) 3 (15) 0.6
Mechanical ventilation on admission, n (%) 5 (25) 15 (75) 0.0005
Mechanical ventilation at day 7, n (%) 2 (10) 7 (35) 0.02
Vasospasm, n (%) 4 (20) 5 (25) 0.9
ICU death, n (%) 2 (10) 5 (25) 0.1
Length of stay in ICU, days 9.5 (6.2-11.3) 12.0 (7.5-16.2) 0.2
Data expressed as median (25th to 75th percentiles) or number (%). WFNS: World Federation of Neurosurgical Societies; ECG: electrocardiography.
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with a worse PaO2/FiO2 ratio compared to patients
with no cardiac dysfunction (355 (254 to 422) versus
445 (421 to 454), P = 0.02).
Relationship between the degree of cardiac dysfunction
in SAH and catecholamine levels
Figure 1 shows that alteration of LV function paralleled
catecholamine levels. Indeed, the degree of abnormal
echocardiographic findings, namely the combined LV
systolic and diastolic dysfunctions (n = 6), was associated
with the highest levels of plasma epinephrine and
norepinephrine (Figure 1). Furthermore, patients with
LV diastolic dysfunction alone had greater plasma levels
of epinephrine and norepinephrine than patients with
no cardiac dysfunction, though only the association
with norepinephrine levels reached statistical significance
(P <0.05) (Figure 1).
In multivariate analysis (including age, norepinephrine
level and WFNS grade), only WFNS grade was statistically
associated with cardiac dysfunction on admission (P = 0.01).
Norepinephrine level was not associated with cardiac
dysfunction on admission (P = 0.27).
Time course of cardiac function and plasma
catecholamine levels during the ICU stay
None of the patients without signs of cardiac dysfunction
on admission developed cardiac dysfunction during the
following ICU stay. In the group with cardiac dysfunction
on admission, a gradual improvement in both LVEF andE’ mean was observed during the first week (Figure 2).
Overall, the number of SAH patients with cardiac dysfunc-
tion decreased over time: on day 1, 25% of patients (5/20)
and on day 7, 70% (14/20) did recover showing a normal
echocardiography (defined by LVEF >50% and absence of
diastolic dysfunction criteria) [19].
In parallel to improvement in echocardiographic
parameters, SAH patients with cardiac dysfunction
had undetectable troponin I plasma levels on day 7,
while BNP plasma levels decreased but remained above
normal values on day 7 (Figure 2). Figure 2 further shows
that plasma levels of catecholamines decreased in the
group of SAH-patients with cardiac dysfunction from
baseline towards levels measured in SAH-patients with no
cardiac dysfunction, at day 1 for epinephrine and later for
norepinephrine.
Association with clinical SAH severity
Table 1 show that, the most severe SAH had a global
ventricular dysfunction affecting both systolic and diastolic
functions. Interestingly, measured cardiac biomarkers and
catecholamines were higher in patients with clinical severe
SAH compared to non-severe SAH (all P <0.05).
Discussion
Our study confirmed that a large proportion of SAH
patients admitted to the ICU showed echocardiographic
and biological signs of cardiac injury. As previously
described, our study showed that the severity of cardiac
injury was associated with the degree of catecholamine






n = 20 n = 20
Hemodynamics and respiratory parameters during echocardiography
Systolic arterial pressure, mmHg 123 (110 to 138) 126 (113 to 149) 0.2
Diastolic arterial pressure, mmHg 63 (58 to 72) 72 (65 to 84) 0.01
Mean arterial pressure, mmHg 81 (76 to 91) 90 (82 to 101) 0.06
Heart rate, beats per minute 63 (57 to 80) 68 (63 to 85) 0.2
PaO2/FiO2 ratio 445 (421 to 454) 355 (254 to 422) 0.02
Echographic parameters
Left ventricular ejection fraction, % 64 (61 to 70) 60 (47 to 67) 0.04
Stroke volume, ml 81 (71 to 90) 72 (51 to 87) 0.2
Cardiac output, l/minute 5.2 (4.9 to 6.4) 4.6 (3.9 to 5.7) 0.53
Left atrium volume, ml/m2 15.6 (12.4 to 18.8) 15.9 (12.7 to 18.6) 0.59
E wave, cm/s 97 (83 to 102) 64 (50 to 94) 0.004
A wave, cm/s 66 (59 to 74) 65 (53 to 91) 0.4
E/A 1.3 (1.2 to 1.6) 1 (0.78 to 1.1) 0.004
E’ lateral, cm/s 15 (14 to 17) 7.5 (6 to 9) <0.0001
E/E’ lateral ratio 6 (5.1 to 6.8) 9 (7.1 to 10) 0.0003
E’ mean, cm/s 13 (11.5 to 16.5) 7.2 (6 to 8.2) <0.0001
PAPs, mmHg 21 (16 to 27) 22 (16 to 32) 0.6
TAPSE, mm 24 (21 to 27) 22 (20 to 24) 0.07
S wave tricuspid, cm/s 15 (14 to 17) 17 (15 to 19) 0.16
Biological markers
BNP, ng/L) 178 (70 to 264) 291 (148 to 619) 0.02
Troponin Ic, μg/ml 0.01 (0.01 to 0.05) 0.4 (0.01 to 4.61) 0.01
Epinephrine, pmol/L 481 (256 to 728) 838 (498 to 1,656) 0.04
Norepinephrine, pmol/L 2,404 (1,580 to 3,363) 4,917 (2,490 to 9,046) 0.02
Norepinephrine after exclusion of patients receiving exogenous
norepinephrine (n = 35, 18 and 17 respectively)
2,281 (1,519 to 3,264) 3,222 (2,480 to 7,516) 0.01
Dopamine, pmol/L 155 (123 to 231) 282 (169 to 428) 0.03
Data expressed as median (25th to 75th percentile) or number (%). PAPs, pulmonary arterial pressure systolic; TAPSE, tricuspid annular plane systolic excursion;
PaO2, arterial partial pressure of oxygen; FiO2, inspired oxygen fraction; BNP, B-type natriuretic peptide.
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analysis and with the severity of SAH in multivariate
analysis. The evolution of echocardiographic and biological
markers paralleled the evolution of plasma levels of
norepinephrine and epinephrine and returned in most
patients toward normal levels within a week.
Catecholamine release in SAH patients
SAH-induced myocardial dysfunction is associated
with increased blood pressure, increased heart rate
and biological and ECG signs of myocardial injury
[7,11,12]. Thus, it has long been hypothesized that
SAH-induced myocardial dysfunction might be related to
release of catecholamines. Catecholamines (epinephrine
and norepinephrine) have been shown to be released inthe plasma few minutes after the induction of severe SAH
in a preclinical dog model [14]. In that preclinical study,
catecholamine release lasted less than 2 hours and was
followed by a sustained increase in biological markers of
cardiac injury and alterations of myocardial function [14].
Our study shows that as reported in the literature [15,27],
there is already marked and rapid catecholamine release
at admission. The source of SAH-induced catecholamine
release remains unknown. It has been suggested that it
might be related to hypothalamic injury [28] or the
presence of a right temporal hematoma associated with
the hemorrhage [27]. This remains to be explored.
In our study, a mild release of catecholamines was
associated with an isolated LV diastolic dysfunction,
whereas the massive catecholamine release seen in the
Figure 1 Clinical, echocardiographic and biological parameters at baseline among patients with systolic-diastolic dysfunction, diastolic
dysfunction or no cardiac dysfunction, mean (SD). Black bars, patients with no cardiac dysfunction (n = 20); dark gray bars, patients with left
ventricular diastolic dysfunction (n = 14); light gray bars, patients with left ventricular systolic-diastolic dysfunction (n = 6): *P <0.05, **P <0.01,
***P <0.001 for comparison between cardiac dysfunction and no cardiac dysfunction at baseline. WFNS, World Federation of Neurosurgical
Societies; LVEF, left ventricular ejection fraction.
Salem et al. Critical Care 2014, 18:558 Page 7 of 10
http://ccforum.com/content/18/6/558more severe forms of SAH was associated with the
alteration of the global myocardial function including
both systolic and diastolic LV functions.
Our study further showed that the restoration of echo-
cardiographic and biological parameters paralleled the
decrease in plasma catecholamine release.
Echocardiographic and cardiac biomarker findings in SAH
patients
Our study confirmed that LV diastolic dysfunction was
the main echocardiographic finding in SAH patients at
ICU admission, as previously described [9,10]. LV diastolic
dysfunction was associated with increased troponin I
suggesting endocardial ischemia [7,8,10-12,29]. LV diastolic
dysfunction was associated with normal left atrium volume,
suggesting an acute rather than a chronic alteration in LV
diastolic function related to chronic hypertension. Our
study extended those findings and showed that the more
severe SAH patients exerted the more severe cardiac injurywith the highest troponin I and BNP plasma levels and
global cardiac dysfunction on echocardiography. Of note,
70% of patients with echocardiographic abnormalities on
admission had restored cardiac function at day 7. In
parallel, BNP decreased at day 7 though it remained
above normal values. Thus, although the majority of
SAH patients recovered their heart function by day 7,
some SAH patients have persistent echocardiographic
or biological abnormalities at day 7 and should be
followed longer, as previously described [12].
Limitations
SAH patients with cardiac dysfunction were older than
patients without cardiac dysfunction. However, age
difference between patients with and without cardiac
dysfunction could not in itself explain SAH-induced
LV diastolic dysfunction [19], as this cardiac dysfunction
was acute and not chronic, and was regressive during the
first week of hospitalization for SAH. Preexisting heart
Figure 2 Time course of echocardiographic signs and biological parameters during the first week after admission in patients with or
without cardiac dysfunction at baseline. Black bars, patients without cardiac dysfunction (n = 20, 19 and 12 at ICU admission, day 1 and day 7); gray
bars, patients with cardiac dysfunction (n = 20, 17 and 10 at ICU admission, day 1 and day 7): *P <0.05, **P <0.01, ***P <0.001 for comparisons between
groups; §P <0.05 for comparison with baseline values within the same group. LVEF, left ventricular ejection fraction; BNP, B-type natriuretic peptide.
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assessed using Doppler echocardiography had potential
limitations [30]. However, in our study, E, E’ lateral and E’
mean all showed a marked reduction, in favor of a true LV
diastolic dysfunction. Furthermore, pulmonary congestion
related to LV diastolic dysfunction, was present in patients
with those echocardiographic abnormalities.
There was no control group comprising either other
non-central nervous system (CNS) injury ICU patients,
or patients with any other reason for non-CNS etiology
of cardiac dysfunction, in the present study. However,
non-severe SAH (WFNS 1 to 2) was used as com-
parator because the levels of catecholamines in these
patients were within the normal range (<2,500 pmoles/L
and <500 pmoles/L for epinephrine and norepinephrine,
respectively) and they had very few cardiac alter-
ations. Future studies should assess the time course
of catecholamines and cardiac function in non-CNS ICU
patients. Also, long-term outcome was not recorded in
the present study, and the clinical significance of ourobservation was limited to the acute in-hospital course.
Given the single center-design of the study and the
few numbers of included-patients, we cannot exclude
the possibility of selection bias or other systematic
confounders influencing our findings.
As described in the result section, we only found a
simple association between cardiac dysfunction and
catecholamine levels in univariate analysis. In the multi-
variate analysis, only WFNS clinical grade predicted
cardiac dysfunction but not cathecolamine levels. Thus,
the association between catecholamine levels and cardiac
dysfunction is not necessarily cause-and-effect and further
study should assess the direct role of catecholamines in
the occurrence of SAH-related cardiac dysfunction.
Conclusion
Our study showed that cardiac alterations associated with
SAH included LV diastolic function and right ventricular
function that both require careful hydration. However,
international guidelines recommend maintaining euvolemia
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quent brain injury [31]. In order to prevent pulmonary and
other organ congestion related to heart dysfunction, we
strongly advise to perform echocardiography on admission
and to repeat it until full recovery before starting the
triple H therapy. In case echocardiography is not
available, our study suggests the possibility to use
plasma BNP as a surrogate marker, and to consider
BNP plasma level >300 pg/ ml on admission as being
strongly associated with cardiac dysfunction. Our study
further shows that in one third of SAH patients, cardiac
function remained altered as assessed by echo or by high
circulating levels of BNP one week after admission for
SAH; those patients need prolonged follow up by echo or
by measures of circulating BNP.
In summary, the results of the present study show that
cardiac dysfunction occurring after SAH was associated
with marked, rapid and sustained release of several
endogenous catecholamines, and the severity of SAH.
Both myocardial alterations and catecholamine levels
are regressive during the first week of evolution.
Further studies should assess the differential role of
catecholamines and brain injury in the occurrence of
SAH-related cardiac dysfunction.
Key messages
 Cardiac dysfunction occurring during SAH is related
to catecholamine release
 Cardiac echocardiography is normalized in most
patients over the first week
 SAH patients with persistent alteration in cardiac
function at day 7 need prolonged cardiac follow up
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